Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

Axsome Therapeutics Inc. (AXSM)

NASDAQ: AXSM · Pharmaceutical Preparations · New York, NY

Our rating: Positive

Call changed from Cautious to Positive at $139.61, moderate conviction, November 3, 2026.

Breaks if: The Positive view is undermined if revenue growth decelerates below 30% year-over-year in either of the next two quarterly reporting periods, or if trailing twelve-month free cash outflow widens beyond $150M — either outcome would signal that commercial scaling is faltering and the 11.5× revenue multiple cannot be sustained. A drawdown of 35% from the current price without a corresponding deterioration in reported fundamentals would also prompt a full reassessment, as it would suggest the market is pricing in impairment this call does not yet capture.

Key figures

Market value$6.8B
Revenue, last 12 months$865M
Net income, last 12 months−$157M
Free cash flow, last 12 months−$83M
Price to earningsn/a
Free cash flow yield−1.2%
Dividend yield0.0%
Operating margin−17.5%
Return on equity−175.6%
Beta to the S&P 5000.69
Volatility, annualized43.4%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 30, 2026$260M51.9%$-0.25−$10M
June 30, 2026$218M45.5%$-0.99−$33M
March 31, 2026$191M57.4%$-1.26−$21M
December 31, 2025$196M65.0%$-0.55−$19M
September 30, 2025$171M63.2%$-0.94$988000.00
June 30, 2025$150M72.1%$-0.97−$32M
March 31, 2025$121M62.0%$-1.22−$44M
December 31, 2024$119M66.0%$-1.54−$26M

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

15 ledger entries and 35 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.